TCRT Stock Overview
A clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Alaunos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.07 |
| 52 Week High | US$9.37 |
| 52 Week Low | US$0.66 |
| Beta | -0.26 |
| 1 Month Change | -1.83% |
| 3 Month Change | -28.67% |
| 1 Year Change | -87.91% |
| 3 Year Change | -97.65% |
| 5 Year Change | -98.38% |
| Change since IPO | -97.81% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?
Nov 10
Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology
Oct 04Alaunos posts 51% tumor reduction for lung cancer therapy
Sep 21Alaunos sheds 52% ahead of data readout for T-cell therapy platform
Sep 15Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data
Aug 31Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02
Aug 15Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?
Jul 26Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?
Apr 06Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?
Dec 20Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies
Jun 19ZIOPHARM records sharpest gain in nearly four months
Jun 09Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?
May 11ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?
Mar 09We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely
Jan 15ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022
Jan 14Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients
Dec 21Activist holder wins Ziopharm Oncology board seats
Dec 17Ziopharm Oncology CFO to step down
Dec 14What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?
Nov 23
Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution
Nov 20ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Ziopharm Oncology thumbs down on investor's call for board seats
Nov 02Shareholder Returns
| TCRT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.1% | 0.7% | 1.2% |
| 1Y | -87.9% | 5.0% | 27.7% |
Return vs Industry: TCRT underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: TCRT underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| TCRT volatility | |
|---|---|
| TCRT Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TCRT's share price has been volatile over the past 3 months.
Volatility Over Time: TCRT's weekly volatility has decreased from 22% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1 | Dale Hogue | www.alaunos.com |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.
Alaunos Therapeutics, Inc. Fundamentals Summary
| TCRT fundamental statistics | |
|---|---|
| Market cap | US$17.13m |
| Earnings (TTM) | -US$26.77m |
| Revenue (TTM) | US$6.00k |
2,856x
P/S Ratio-0.6x
P/E RatioIs TCRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCRT income statement (TTM) | |
|---|---|
| Revenue | US$6.00k |
| Cost of Revenue | US$16.28m |
| Gross Profit | -US$16.27m |
| Other Expenses | US$10.50m |
| Earnings | -US$26.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.67 |
| Gross Margin | -271,216.67% |
| Net Profit Margin | -446,233.33% |
| Debt/Equity Ratio | 0% |
How did TCRT perform over the long term?
See historical performance and comparison